- Home
- PHAT vs NETD Comparison
PHAT vs NETD Comparison
Compare PHAT & NETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- NETD
- Stock Information
- Founded
- PHAT 2018
- NETD 2023
- Country
- PHAT United States
- NETD United States
- Employees
- PHAT N/A
- NETD N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- NETD
- Sector
- PHAT Health Care
- NETD
- Exchange
- PHAT Nasdaq
- NETD Nasdaq
- Market Cap
- PHAT 465.0M
- NETD 412.5M
- IPO Year
- PHAT 2019
- NETD 2023
- Fundamental
- Price
- PHAT $6.96
- NETD $10.82
- Analyst Decision
- PHAT Strong Buy
- NETD
- Analyst Count
- PHAT 4
- NETD 0
- Target Price
- PHAT $23.00
- NETD N/A
- AVG Volume (30 Days)
- PHAT 971.9K
- NETD 57.0K
- Earning Date
- PHAT 03-06-2025
- NETD 01-01-0001
- Dividend Yield
- PHAT N/A
- NETD N/A
- EPS Growth
- PHAT N/A
- NETD N/A
- EPS
- PHAT N/A
- NETD 0.45
- Revenue
- PHAT $26,270,000.00
- NETD N/A
- Revenue This Year
- PHAT $7,622.43
- NETD N/A
- Revenue Next Year
- PHAT $236.87
- NETD N/A
- P/E Ratio
- PHAT N/A
- NETD $24.07
- Revenue Growth
- PHAT N/A
- NETD N/A
- 52 Week Low
- PHAT $6.07
- NETD $10.38
- 52 Week High
- PHAT $19.71
- NETD $10.83
- Technical
- Relative Strength Index (RSI)
- PHAT 37.02
- NETD 62.37
- Support Level
- PHAT $6.36
- NETD $10.81
- Resistance Level
- PHAT $7.20
- NETD $10.83
- Average True Range (ATR)
- PHAT 0.48
- NETD 0.02
- MACD
- PHAT 0.08
- NETD -0.00
- Stochastic Oscillator
- PHAT 30.48
- NETD 70.00
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.